Could a diabetes drug help hearts stiffened by amyloid?

NCT ID NCT07240844

Recruiting now Disease control Sponsor: Seoul St. Mary's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Enavogliflozin, a drug used for diabetes, can help people with amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. About 68 adults with heart failure symptoms will take the drug or a placebo for 12 weeks, then switch. The main goal is to see if the drug improves heart-related symptoms and daily function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Enavogliflozin
What this could lead to: If it works, this could offer a new treatment option to improve heart function and quality of life in people with amyloid cardiomyopathy.
What could go wrong: This is a small, early-phase trial with only 68 participants. The drug may not show significant benefit over placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial restrictive cardiomyopathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID CARDIOMYOPATHY

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Seoul St. Mary's Hospital, The Catholic University of Korea
RECRUITING

Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.